Cubist Systematic Strategies, LLC Curis Inc Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.74 - $15.01 $13,315 - $270,089	-17,994 Reduced 52.26%	16,438 $12,000
Q2 2022 Aug 15, 2022	SELL	$0.71 - $2.43 $111,137 - $380,372	-156,532 Reduced 81.97%	34,432 $34,000
Q1 2022 May 16, 2022	BUY	$2.31 - $5.13 $109,671 - $243,557	47,477 Added 33.09%	190,964 $454,000
Q4 2021 Feb 14, 2022	BUY	$4.45 - $8.09 $557,949 - $1.01 Million	125,382 Added 692.53%	143,487 $683,000
Q3 2021 Nov 15, 2021	BUY	$6.94 - $8.85 $119,555 - $152,458	17,227 Added 1962.07%	18,105 $142,000
Q2 2021 Aug 16, 2021	SELL	$7.45 - $16.27 $714,581 - $1.56 Million	-95,917 Reduced 99.09%	878 $7,000
Q1 2021 May 17, 2021	BUY	$8.78 - $12.8 $849,860 - $1.24 Million	96,795 New	96,795 $1.1 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.